Childhood Liver Cancer Treatment (PDQ®)–Health Professional Version
SECTIONS
- General Information About Childhood Liver Cancer
- Cellular Classification of Childhood Liver Cancer
- Tumor Stratification by Imaging and Postsurgical Staging for Childhood Liver Cancer
- Treatment Option Overview for Childhood Liver Cancer
- Hepatoblastoma
- Hepatocellular Carcinoma
- Undifferentiated Embryonal Sarcoma of the Liver
- Infantile Choriocarcinoma of the Liver
- Current Clinical Trials
- Changes to This Summary (08/10/2017)
- About This PDQ Summary
- View All Sections
Changes to This Summary (08/10/2017)
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.
Added Special Considerations for the Treatment of Children With Canceras a new subsection.
Revised text to state that the finding of an alpha-fetoprotein level of 100 to 1,000 ng/mL was significant only among patients younger than 8 years in the backbone PRETEXT III group.
Added Treatment options under clinical evaluation for hepatoblastomaas a new subsection.
Added Treatment options under clinical evaluation for hepatocellular carcinoma as a new subsection.
Added text about the APEC1621 (NCT03155620) trial as a treatment option under clinical evaluation.
Added Treatment Options Under Clinical Evaluation for Infantile Choriocarcinoma of the Liver as a new subsection.
This summary is written and maintained by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.
No hay comentarios:
Publicar un comentario